TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.
TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.
The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.
A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.
You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 in Paris, France on Oct. 29th. Agenda included.
This interactive workshop is held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The workshop is intended to provide clinicians, researchers, students and representatives from regulatory non-government organizations active in the TB-field with a platform for presentation and discussion of the latest scientific developments in the field. The workshop will allow [...]
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) failed to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). A letter from the Treatment Action Group criticizing this decision is included.
Sequella today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).
Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.
We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.